Business
InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Feb. 5, 2019\n\n\n\nTSX:IN OTCQX:IMLFF\n VANCOUVER, Feb. 5, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX: IN) (OTCQX: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three months ended December 31, 2018, which is the Company's second quarter of fiscal year 2019 (\"2Q19\"), on Monday, February 12, 2019.\n\n \n \n\n \n \nConference Call & Webcast:\nTuesday, February 12, 2019 at 10:00 AM Pacific Time, 1:00 PM Eastern Time\nToronto:\n+1-416-764-8688\nVancouver:\n+1-778-383 7413\nNorth America (Toll Free):\n+1-888-390 0546\nConference ID:\n57006422\nWebcast:\nhttps://event.on24.com/wcc/r/1927913/EAFF479A341D7F67741B5E1724322F94\n \nReplays, Available through February 19, 2019:\nToronto:\n+1-416-764-8677\nNorth America (Toll Free):\n+1-888-390-0541\nPlayback Passcode:\n006422 #\n \nThe Company's full financial statements and related MD&A for the three months ended December 31, 2018 will be available at www.sedar.com on February 12, 2019.\nAbout InMed: InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynt...